MarginsXMarginsX
Home › Markets › Health Care › ICCC

ImmuCell Corporation (ICCC)

ICCC trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.42
+6.23% on the day
Market cap
$103.8M
Micro cap
Revenue · 2025
$27.6M
+4.3% on 2024
Net income · 2025
-$1.0M
-3.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/0001437749-26-010339-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerICCC on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO year1987
SEC CIK0000811641
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2025

LineValue
Revenue$27.6M
Net income-$1.0M
Operating income$1.6M
Net margin-3.8%
Operating margin6.0%
Revenue growth+4.3%
Cash$3.8M
Total assets$42.5M
P/E (computed)Net income was not positive
P/S (computed)3.8×

Warning signs

Cash runway
Cash-flow positive
$7.9M cash at September 30, 2026
Share count, 1 year
+0.5%
2025-10-31 to 2026-10-30 · +17.3% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$172K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$7.9M cash; operating cash flow $2.0M a quarter.Report 2026-09-30
Shares outstanding9,091,361 (2026-10-30); 9,045,851 a year earlier; 7,750,864 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWipfli LLP, Radnor, Pennsylvania, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $172K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$8.0M$953K$756K$7.9M$7.9M$33.2M10-Q 2026-11-12
Q2 2026
2026-06-30
$7.2M$1.8M$3.0M$8.9M$8.3M$30.7M10-Q 2026-08-13
Q1 2026
2026-03-31
$10.4M$1.9M$3.6M$6.8M$8.7M$29.9M10-Q 2026-05-14
Q4 2025
2025-12-31
$7.6M-$2.8M$483K$3.8M$9.1M$27.6M10-K 2026-03-30
Q3 2025
2025-09-30
$5.5M-$140K-$1.2M$3.9M$9.5M$27.8M10-Q 2026-11-12
Q2 2025
2025-06-30
$6.4M$502K$1.6M$6.0M$9.8M$28.3M10-Q 2025-08-14
Q1 2025
2025-03-31
$8.1M$1.4M$1.6M$4.6M$10.2M$27.3M10-Q 2025-05-14
Q4 2024
2024-12-31
$7.8M$515K-$3K$3.8M$10.5M$26.5M10-K 2025-03-28

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B22024-04-10
Latest annual report
FORM 10-K/A
10-K/A2026-05-13
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-13
Latest proxy
FORM DEF 14A
DEF 14A2026-04-24

Source: SEC EDGAR submissions feed, 799 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+9.7%
1 month-0.4%
3 months-1.4%
Year to date+74.8%
1 year+77.7%
From 52-week high-8.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
IMDXInsight Molecular Diagnostics Inc.$1.86-13.08%$60.9M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M
MYGNMyriad Genetics Inc.$5.57-1.59%$534.3M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
VNRXVolitionRX Limited$0.1998-13.13%$7.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier